Analysis

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis

Rocket Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to RCKT.

websiteRCKT/analysis/RCKT

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to RCKT.

Stock profile

Ticker

RCKT

Asset type

Stock

Market cap

$365.8M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Rocket Pharmaceuticals, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • RCKT primary listing
  • A2JA9Q
  • 9IP1

Latest Rocket Pharmaceuticals, Inc. news

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

CRANBURY, N.J., May 07, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic...

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

CRANBURY, N.J., April 28, 2026--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genet...

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe Leukocyte Adhesion

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric

Research sections

Valuation

Review valuation context for Rocket Pharmaceuticals, Inc..

Future growth

Review future growth context for Rocket Pharmaceuticals, Inc..

Past performance

Review past performance context for Rocket Pharmaceuticals, Inc..

Financial health

Review financial health context for Rocket Pharmaceuticals, Inc..

Dividend

Review dividend context for Rocket Pharmaceuticals, Inc..

Management

Review management context for Rocket Pharmaceuticals, Inc..

Ownership

Review ownership context for Rocket Pharmaceuticals, Inc..

Other information

Review other information context for Rocket Pharmaceuticals, Inc..

Community

Review community context for Rocket Pharmaceuticals, Inc..